Herborium Group, Inc. Enters Acne Treatment Market in the UK With the Introduction and Commencement of Sales of AcnEase(R), Its
May 21 2009 - 8:00AM
Marketwired
Herborium Group, Inc. (OTCBB: HBRM), a botanical therapeutics�
company that develops, licenses and markets novel, botanical
ingredient based medicinal products, today announced that it has
entered into a long-term distribution Agreement with the largest
retailer of male grooming products in the UK, Mankind LLC. In
addition to its leading market share of the male grooming market,
Mankind also commands a sizeable market share of the UK Internet
female cosmetic market.
"We are very excited about the potential for AcnEase�, our
novel, herbal acne treatment, in the UK," said Dr. Agnes P.
Olszewski, CEO of Herborium Group. "The Dermatology Market Outlook
for 2011 forecasts that, collectively, the acne market is estimated
to be $2.7 billion in 2011. The major dermatological indications
included in this market are acne, the largest segment, and Rosacea
the fifth largest segment, both of which are treated successfully
by AcnEase. In clinical studies AcnEase� has demonstrated up to 95%
efficacy in diminishing acne and improving skin condition. The
market for natural based products in the UK is estimated to be over
$25 billion. Sales of AcnEase� in the UK have commenced and we
expect steady growth in 2009 and beyond, since our product fits the
growing market need for all natural and safe products, as well as
the high demand for acne (dermatologic) treatments."
Herborium editorial on Acne Treatment has been selected for
publication by NATIONAL ASSOCIATION of PRIMARY CARE REVIEW - Summer
2009, a leading journal targeting General Practitioners and the GP
Trusts in the UK.
For more information about Herborium and AcnEase visit the
following links: www.herborium.com and www.acnease.com
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics� company, is
focused on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company business model focuses on emerging
market opportunities spearheaded by the growth of a new market
sector located between high-cost, high-risk, ethical
pharmaceuticals and commoditized classic nutraceuticals
(supplements). The Company uses clinical validation and a proactive
regulatory strategy based on the FDA Guidance for Industry:
Botanical Drug Products (FDA Guidance 2004) to establish and
maintain a differential advantage. Herborium harvests its
therapeutic candidates from Traditional Chinese Medicine and
utilizes Western regulatory, clinical and marketing strategies to
successfully introduce the products to Western markets. The company
has secured a pipeline of botanical ingredients based products in
the areas of dermatological needs, Prostate Health (BPH), Liver
Diseases, Women's Health and selected sexual disorders resulting
from cardiovascular disease, use of anti-depressants, surgical
procedures, and other problems. Herborium Group sells its products
in the United States, the United Kingdom, and continental Europe
through a network of distributors, specialty retailers, and
e-commerce.
Safe Harbor Statement: This release contains forward-looking
statements with respect to the results of operations and business
of Sunrise Consulting Group, Inc., which involves risks and
uncertainties. The Company's actual future results could materially
differ from those discussed. The Company intends that such
statements about the Company's future expectations, including
future revenues and earnings, and all other forward looking
statements be subject to the "Safe Harbors" provision of the
Private Securities Litigation Reform Act of 1995.
Contact: Herborium Group, Inc. Dr. Agnes Olszewski CEO 201 647
3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From May 2024 to Jun 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2023 to Jun 2024